

NEWS & VIEWS REFERENCES

1. Cregan-Reid V. Primate Change. Octopus Publishing Group, 20 Sept 2018
2. Cregan-Reid V. Anthropocene: why the chair should be the symbol for our sedentary age. The Conversation, 26 Oct 2018. Available at <https://theconversation.com/anthropocene-why-the-chair-should-be-the-symbol-for-our-sedentary-age-105319>
3. van Baar A, et al. Duodenal Mucosal Resurfacing Elicits Improvement in Glycemic and Hepatic Parameters in Type 2 Diabetes—One-Year Multicenter Study Results. *Diabetes* Jul 2018, 67 (Supplement 1) 1137-P
4. Diabetes UK. Position statement: diabulimia. Available at <https://www.diabetes.org.uk/professionals/news--updates/our-new-position-statement-on-diabulimia>
Accessed 29 Oct 2018
5. Pinhas-Hamiel O, Levy-Shraga Y. Eating disorders in adolescents with Type 2 and Type 1 diabetes. *Current Diabetes Reports* 2013. 13(2):289-97
6. Herpertz S, et al. Comorbidity of diabetes mellitus and eating disorders: A follow-up study. *J Psychosom Res.* 2001;51:673–8
7. Peyrot M, et al. Correlates of insulin injection omission. *Diabetes Care.* 2010;33:240–5
8. Olmsted MP, et al. Prediction of the onset of disturbed eating behavior in adolescent girls with type 1 diabetes. *Diabetes Care* 2008;31:1978-1982

FEATURE REFERENCES

P 8-11 Cardiovascular screening in diabetes:

1. Diabetic cardiovascular disease. (n.d.). Retrieved from <https://bestpractice.bmj.com/topics/en-us/533>
2. Mancini, G.B., et al., Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. *J Am Coll Cardiol*, 2016. 68(10): p. 985-95.
3. Australian Heart and Stroke Charter. (2018). 1st ed. [ebook] Available at: https://www.heartfoundation.org.au/images/uploads/main/Get_Involved/Australian_Heart_Stroke_Charter.pdf [Accessed 4 Oct. 2018].
4. Makrilakis, K., & Liatis, S. (2017). Cardiovascular Screening for the Asymptomatic Patient with Diabetes: More Cons Than Pros. *Journal of diabetes research*, 2017.
5. Kumar, S., & Colman, P. (2017). Diabetes complications: prevention and screening.
6. W. E. Boden, R. A. O'Rourke, K. K. Teo et al., "Optimal medical therapy with or without pci for stable coronary disease," *The New England Journal of Medicine*, vol. 356, no. 15, pp. 1503–1516, 2007.
7. Muhlestein, J. B., Lappé, D. L., Lima, J. A., Rosen, B. D., May, H. T., Knight, S., ... & Vavere, A. L. (2014). Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. *Jama*, 312(21), 2234-2243.
8. Aschner, P. (2017). New IDF clinical practice recommendations for managing type 2 diabetes in primary care.

9. Lalor, E., Boyden, A., Cadilhac, D., Colagiur, S., Doust, J., Fraser, D., ... & Lusic, N. (2012). Guidelines for the management of absolute cardiovascular disease risk.
10. D. V. Rados, L. C. Pinto, C. B. Leitão, and J. L. Gross, "Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis," *BMJ Open*, vol. 7, no. 5, article e015089, 2017.
11. Muhlestein JB, Lappe DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the Factor-64 randomized clinical trial. *JAMA*. 2014;312:2234. doi: 10.1001/jama.2014.15825.
12. Allan, G. M., Nouri, F., Korownyk, C., Kolber, M. R., Vandermeer, B., & McCormack, J. (2013). Agreement among cardiovascular disease risk calculators. *Circulation*, CIRCULATIONAHA-112.
13. Hamilton-Craig, C., Liew, G., Chan, J., Chow, C., Jelinek, M., van Pelt, N., & Younger, J. Coronary Artery Calcium Scoring—Position Statement.
14. Weir, M. R. (2007). Microalbuminuria and cardiovascular disease. *Clinical Journal of the American Society of Nephrology*, 2(3), 581-590.
15. American Diabetes Association. (2018). 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. *Diabetes care*, 41(Supplement 1), S86-S104.
16. Aschner, P. (2017). New IDF clinical practice recommendations for managing type 2 diabetes in primary care.
17. Ackermann, E., Harris, M. F., Alexander, K., Arcus, M., Bailey, L., Bennett, J. W., ... & Fasher, M. (2012). Guidelines for Preventive Activities in General Practice.
18. Authors/Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., ... & Huikuri, H. (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European heart journal*, 34(39), 3035-3087.
19. Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., ... & Landefeld, C. S. (2018). Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement. *JAMA*, 319(22), 2308-2314.
20. Chou, R. (2015). Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians. *Annals of internal medicine*, 162(6), 438-447.
21. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. *Diabetol Metab Syndr*. 2017;9:25.
22. Elhendy A., Arruda A.M., Mahoney D.W., Pellikka P.A. (2001) Prognostic stratification of diabetic patients by exercise echocardiography. *J Am Coll Cardiol* 37:1551–1557
23. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors. Hayashino Y, Nagata-Kobayashi S, Morimoto T, Maeda K, Shimbo T, Fukui T. *J Gen Intern Med*. 2004 Dec; 19(12):1181-91.
24. Lee JC, West MJ, Khafagi FA. Myocardial perfusion scans. *Australian family physician*. 2013 Aug;42(8):564.

25. Gupta, A., & Bajaj, N. S. (2017). Reducing radiation exposure from nuclear myocardial perfusion imaging: Time to act is now.
26. Lau, K., Sippel, J., Westerink, A., Dobeli, K., & Younger, J. (2016). Comparison of Radiation dose Between Computer Tomography Coronary Angiography (CTCA) and Invasive Coronary Angiography (ICA) in Severely Obese Patients. *Heart, Lung and Circulation*, 25, S221-S222.
27. Celeng, C., Maurovich-Horvat, P., Ghoshhajra, B. B., Merkely, B., Leiner, T., & Takx, R. A. (2016). Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis. *Diabetes Care*, 39(7), 1274-1280.
28. Leong, K., Einsiedel, P., Lui, E., Better, N., Heinze, S., Neal, C., ... & Joshi, S. (2013). Comparison of Radiation Doses Between Coronary CT and Conventional Coronary Angiography. *Heart, Lung and Circulation*, 22, S169-S170.

P12-13 Cardiovascular disease prevention in diabetes

1. Aschner, P. (2017). New IDF clinical practice recommendations for managing type 2 diabetes in primary care.
2. Lalor, E., Boyden, A., Cadilhac, D., Colagiur, S., Doust, J., Fraser, D., ... & Lusic, N. (2012). Guidelines for the management of absolute cardiovascular disease risk.
3. Ackermann, E., Harris, M. F., Alexander, K., Arcus, M., Bailey, L., Bennett, J. W., ... & Fasher, M. (2012). Guidelines for Preventive Activities in General Practice.
4. Deed, G., Ackermann, E., Arthur, I., Barlow, J., Jagadeesan, S., Kawol, D., ... & Saleh, A. (2016). General Practice Management of Type 2 Diabetes: 2016–18.
5. Aschner, P. (2017). New IDF clinical practice recommendations for managing type 2 diabetes in primary care.
6. Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., ... & Look AHEAD Research Group. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes care*, DC_102415.
7. Hu, G., Jousilahti, P., Barengo, N. C., Qiao, Q., Lakka, T. A., & Tuomilehto, J. (2005). Physical activity, cardiovascular risk factors, and mortality among Finnish adults with diabetes. *Diabetes care*, 28(4), 799-805.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665.
9. Gabb, G. M., Mangoni, A., Anderson, C. S., Cowley, D., Dowden, J. S., Gollidge, J., ... & Schlaich, M. (2016). Guideline for the diagnosis and management of hypertension in adults—2016. *mortality*, 3(4).
10. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med*. 2010 Jun 28;170(12):1024-31
11. Polsky, S., & Akturk, H. K. (2017). Alcohol consumption, diabetes risk, and cardiovascular disease within diabetes. *Current diabetes reports*, 17(12), 136.

P14-16 PCOS and diabetes: New management guidelines

1. Yilmaz B, Vellanki P, Ata B, Yildiz BO. Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. *Fertility and sterility*. 2018;109(2):356.
2. Barber T, Franks S. Genetic basis of polycystic ovary syndrome. *Expert Review of Endocrinology & Metabolism*. 2010;5(4):549-561.
3. Ünlütürk U, Sezgin E, Yildiz BO. Evolutionary determinants of polycystic ovary syndrome: part 1. *Fertility and Sterility*. 2016;106(1):33-41.
4. Fessler DMT, Natterson-Horowitz B, Azziz R. Evolutionary determinants of polycystic ovary syndrome: part 2. *Fertility and Sterility*. 2016;106(1):42-47.
5. Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. *Nat Med*. 2018.
6. Norman R, Teede H. Polycystic ovary syndrome. *Medical Journal of Australia*. 2018;In press.
7. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Human Reproduction*. 2010;25(2):544-551.
8. Boyle JA CJ, O'Dea K, Dunbar T, Norman RJ. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. *Med J Aust*. 2012;196(1):62-66.
9. Yildiz BO, Bozdogan G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Human Reproduction*. 2012;27(10):3067-3073.
10. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Trends in Molecular Medicine*. 2006;12(7):324-332.
11. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Medicine*. 2010;8:41.
12. Deeks A, Gibson-Helm M, Teede H. Is having polycystic ovary syndrome (PCOS) a predictor of poor psychological function including depression and anxiety. *Hum Reprod*. 2011;Advance access published March 23, 2011.
13. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Medicine*. 2010;8(1):41.
14. Boomsma C, Eijkemans M, Hughes E, Visser G, Fauser B, Macklon N. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Human Reproduction Update*. 2006;12(6):673-683.
15. Apridonidze T, Essah P, Luorno M, Nestler J. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *Journal of Clinical Endocrinology & Metabolism*. 2005;90(4):1929-1935.
16. Legro R, Kusanman A, Dodson W, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. *Journal of Clinical Endocrinology & Metabolism*. 1999;84(1):165-168.
17. Escobar-Morreale HF, Roldán-Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. *Diabetes care*. 2016;39(4):639.
18. Thong E, Joham AE, Milat F, Ranasinha S, Mishra G, HJ. T. Contemporary risk of menstrual and reproductive dysfunction in women with Type 1 diabetes: a population-based study. Annual Scientific Meetings of the Endocrine Society of Australia and the Society for Reproductive Biology; 2018; Adelaide, Australia, .

19. Codner E, Merino PM, Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. *Human Reproduction Update*. 2012;18(5):568-585.
20. Teede HJ, Costello M.F, Dokras A, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Clinical Endocrinology, in press*. 2018.
21. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. *Fertil Steril*. 1994;61(4):598-604.
22. Teede HJ, Joham AE, Paul E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. *Obesity (Silver Spring, Md)*. 2013;21(8):1526-1532.
23. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. *The Journal of clinical endocrinology and metabolism*. 1999;84(4):1470-1474.
24. Panico A, Messina G, Lupoli GA, et al. Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome. *Patient preference and adherence*. 2017;11:423-429.
25. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. *Human Reproduction Update*. 2011;17(2):171-183.
26. Keshel TE, Coker RH. Exercise Training and Insulin Resistance: A Current Review. *Journal of obesity & weight loss therapy*. 2015;5(0 5):S5-003.
27. Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. *BMJ Open Sport — Exercise Medicine*. 2016;2(1):e000143.
28. Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. *Drugs*. 2015;75(10):1071-1094.
29. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Fertility and Sterility*.
30. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. *Diabetes, obesity & metabolism*. 2017;19(4):473-481.
31. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes. *The New England journal of medicine*. 2014;370(21):2002-2013.
32. Christ JP, Falcone T. Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS). *Obesity surgery*. 2018;28(8):2171-2177.
33. Narayanan RP, Syed AA. Pregnancy Following Bariatric Surgery—Medical Complications and Management. *Obesity surgery*. 2016;26(10):2523-2529.

P18-19 New diabetes medications – which T2D agents actually save lives?

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352(9131):837-53.
2. Stratton IM, Alder AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *British Medical Journal*. 2000;321:405-12.
3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545-59.

4. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008;358(24):2560-72.
5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009;360(2):129-39.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008;359(15):1577-89.
7. Davis TM, Chubb SA, Bruce DG, Davis WA. Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetes Obes Metab.* 2016;18(6):598-606.
8. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia.* 2018.
9. Joffe HV, Parks MH, Temple R. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. *Rev Endocr Metab Disord.* 2010;11(1):21-30.
10. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med.* 2013;369(14):1317-26.
11. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med.* 2013;369(14):1327-35.
12. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2015;373(3):232-42.
13. Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINagliptin (CARMELINA((R))): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. *Cardiovasc Diabetol.* 2018;17(1):39.
14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015;373(22):2117-28.
15. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 2017;377(7):644-57.
16. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med.* 2015;373(23):2247-57.
17. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2016;375(4):311-22.
18. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-44.
19. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2017;377(13):1228-39.

20. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018.

p22-23 Fit for it – Exercise prescription for T2D & cardiovascular disease

1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. *Diabetes Care*. 2004 Aug 1;27(8):1879-84.
2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. *Diabetes Care*. 2010 Feb 1;33(2):442-9.
3. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovascular Diabetology*. 2018;17:83. doi:10.1186/s12933-018-072
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *New England Journal of Medicine*. 1998 Jul 23;339(4):229-34.
5. Anderson LJ, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. *International Journal of Cardiology*. 2014 Dec 15;177(2):348-61
6. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, Tonoli C, Greco E, Fagard R, Coninx K, Vanhees L. Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group. *Sports Medicine*. 2018 May 4:1-7.
7. Borghouts LB, Keizer HA. Exercise insulin sensitivity: a review. *Int J Sports Med* 2000;21:1–12.
8. Gulve EA. Exercise and glycemic control in diabetes: benefits, challenges, and adjustments to pharmacotherapy. *Physical Therapy*. 2008 Nov 1;88(11):1297-321.
9. Handbook Of Non Drug Intervention (HANDI) Project Team. Exercise based rehabilitation for coronary heart disease [Internet]. [cited 2018 Sept]. Available from: <https://www.racgp.org.au/your-practice/guidelines/handi/interventions/cardiovascular/exercise-based-rehabilitation-for-coronary-heart-disease/>
10. Selig SE, Levinger I, Williams AD, Smart N, Holland DJ, Maiorana A, Green DJ, Hare DL. Exercise & Sports Science Australia Position Statement on exercise training and chronic heart failure. *Journal of Science and Medicine in Sport*. 2010 May 1;13(3):288-94.

P24-27 Making medication ‘adherence’ irrelevant

To come from Dr Linda Beeney

P28-29 Reality Check: overweight Aussie children

1. Spurrier NJ, Magarey A, Wong C. Recognition and management of childhood overweight and obesity by clinicians. *J Paed Child Health* 2006;42: 411- 418

2. Freedman DS, et al. The relation of childhood BMI to adult adiposity: The Bogalusa Heart Study. *Pediatrics* 2005; 115: 22-7.
3. Xu J, Hardy JL, Guo CZ, Garnett SP. The trends and prevalence of obesity and morbid obesity among Australian school-aged children, 1985-2014. *J Paed Child Health* 2018; 54: 907-912.
4. Mhrshahni S, Gow ML, Baur LA. Contemporary approaches to the prevention and management of paediatric obesity: an Australian focus. *Med J Aust* 2018; 209: 267-274.
5. Moore MJ, McKee M, Brownbill AL. Protecting our children from obesity: challenges and opportunities. (Editorial). *Med J Aust* 2018; 209: 253-252.
6. Smithers LG, Haag DG, Agnew B, et al. Food advertising on Australian television: Frequency, duration and monthly pattern of advertising from a commercial network (four channels) for the entire 2016. *J Paed Child Health* 2018; 54: 962-967.

p32-34 Food Stuff: The sugar wars

1. Australian Food and Grocery Council. Greens sugar tax (GST) an attack on regional jobs. Media release, 22 June 2016. Available at: <https://www.afgc.org.au/2016/06/greens-sugar-tax-gst-an-attack-on-regional-jobs/>
2. Imamura F, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. *Br J Sports Med* 2016;50:496-504.
3. Pym H. Sugar tax is already producing results. BBC News, 12 March 2018. Available at: <https://www.bbc.com/news/health-43372295>
4. Veerman JL, et al. The Impact of a Tax on Sugar-Sweetened Beverages on Health and Health Care Costs: A Modelling Study. 2016, *PLoS ONE* 11(4): e0151460
5. Nomaguchi T, et al. The impact on productivity of a hypothetical tax on sugar-sweetened beverages. *Health Policy*, 2017 Jun;121(6):715-725
6. Lal A, et al. Modelled health benefits of a sugar-sweetened beverage tax across different socioeconomic groups in Australia: A cost-effectiveness and equity analysis. 2017, *PLoS Med* 14(6): e1002326
7. Powell LM, et al. Employment impact of sugar-sweetened beverage taxes. *Am J Public Health*. 2014;104(4):672-7.
8. Silver L, et al. Changes in prices, sales, consumer spending, and beverage consumption one year after a tax on sugar-sweetened beverages in Berkeley, California, US: A before-and-after study. *PLoS Med*. 2017 Apr 18;14(4):e1002283
9. Guerrero-López C, et al. Employment changes associated with the introduction of taxes on sugar-sweetened beverages and nonessential energy-dense food in Mexico. *Preventive Medicine*. 2017 Dec, vol 105 supp:S43-S49